New therapeutic options for alcohol dependence: Long-acting intramuscular formulations of naltrexone

Journal of Clinical Psychiatry

Volumn 67, Issue SUPPL. 14, 2006, Pages 30-34

  Garbutt, James C ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ALCOHOL ABSTINENCE; ALCOHOLISM; BACKACHE; CLINICAL TRIAL; DECREASED APPETITE; DETOXIFICATION; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LOEFFLER PNEUMONIA; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 33846121269     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. McLellan AT, Lewis DC, O'Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-1695
2. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005;293:1617-1625
3. O'Malley SS, Rounsaville BJ, Farren C, et al. Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials. Arch Intern Med 2003;163:1695-1704
4. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006;295:2003-2017
5. Dawson DA. Alternative measures and models of hazardous consumption. J Subst Abuse 2000;12:79-91
6. Corrao G, Bagnardi V, Zambon A, et al. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004;38:613-619
7. Mark TL, Kranzler HR, Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 2003;71: 219-228
8. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, doubleblind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000;35:587-593
9. Volpicelli JR, Rhines KC, Rhines JS, et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997;54:737-742
10. Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism: results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry 1997;54: 1130-1135
11. Rohsenow DJ, Colby SM, Monti PM, et al. Predictors of compliance with naltrexone among alcoholics. Alcohol Clin Exp Res 2000;24:1542-1549
12. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict 2003;12(suppl 1):S3-S11
13. Kranzler HR, Wesson DR, Billot L. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004;28:1051-1059
14. Pettinati HM. Improving medication adherence in alcohol dependence. J Clin Psychiatry 2006;67(suppl 14):23-29
15. Vivitrol (naltrexone for extended-release injectable suspension)[package insert]. Cambridge, MA: Alkermes, Inc; April 2006
16. Bartus RT, Emerich DF, Hotz J, et al. Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology 2003;28:1973-1982
17. Johnson BA, Ait-Daoud N, Aubin HJ, et al. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcohol Clin Exp Res 2004;28:1356-1361
18. Johnson DAW. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. J Clin Psychiatry 1984;45(5, sec 2):13-21
19. Volpicelli JR, Pettinati HM, McLellan AT, et al. Combining Medication and Psychosocial Treatments for Addictions: The BRENDA approach. New York, NY: The Guilford Press; 2001
20. O'Malley SS, Illeperuma A, Loewy J, et al. Effects of lead-in drinking/ treatment goal with long-acting naltrexone. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
21. Gastfriend DR, Dong Q, Loewy J, et al. Durability of effect of long-acting injectable naltrexone. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga